## 

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases.

Please see the Prevalence Comparison Chapter of this CSR for more information.

Site/Sex	Age at Prevalence									
	All Ages <sup>c</sup>	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70+	
All Sites										
Males	6,872,623	18,786	43,295	91,310	166,204	350,387	937,944	1,835,673	3,429,024	
Females	7,866,096	17,222	37,437	93,801	242,346	639,430	1,424,917	1,995,951	3,414,992	
remaies	7,000,000	11,222	37,437	93,001	242,340	039,430	1,424,517	1,000,001	3,414,992	
Oral Cavity & Pharynx										
Males	230,233	45	454	1,771	3,759	13,831	51,146	76,136	83,090	
Females	116,669	107	542	1,594	4,163	8,877	21,084	30,278	50,024	
Esophagus										
Males	35,460	0	0	29	181	1,003	5,067	12,194	16,986	
Females	10,087	0	0	0	44	190	1,441	2,846	5,566	
Stomach										
Males	55,180	0	11	168	589	2,749	8,310	14,682	28,670	
Females	40,584	0	44	210	842	2,454	5,947	9,160	21,926	
Gallari C. Dantum										
Colon & Rectum Males	652 062	2.2	1.46	1 062	6 240	06.000	01 550	156 206	271 207	
	653,863	22	146	1,263	6,349	26,922	91,558	156,306	371,297	
Females	663,384	0	261	1,482	6,650	24,542	80,676	130,589	419,183	
Liver & Intrahep										
Males	46,895	611	536	603	632	1,608	11,275	19,864	11,766	
Females	19,876	418	591	486	471	1,059	3,816	6,321	6,715	
Pancreas										
Males	31,986	23	35	117	493	1,812	5,719	9,976	13,812	
Females	32,682	0	23	347	628	1,721	5,972	8,601	15,389	
Larynx										
Males	80,249	0	0	80	285	1,810	10,178	23,304	44,592	
Females	19,665	0	0	17	142	859	3,485	5,914	9,247	
Lung & Bronchus										
Males	234,540	34	98	470	1,266	5,330	26,088	64,649	136,605	
Females	292,688	56	92	401	1,684	6,863	35,794	75,197	172,603	
Melanoma of the Skin										
Males	585,672	67	706	4,931	18,016	45,764	104,327	160,068	251,795	
Females	583,679	107	813	10,439	36,175	74,208	129,434	142,681	189,821	
	,			- •		, , , -	.,	,	,	

U.S. 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER 9 registries (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta) and 1/1/2014 U.S. population estimates based on the average of 2013 and 2014 population estimates from the U.S. Bureau of the Census. Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39 years (1975-2013).

Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.

WARNING: The Prevalence Estimates presented on this page utilize a different tumor selection criteria from previous CSR releases and are NOT directly comparable to estimates from previous CSR releases.

Please see the Prevalence Comparison Chapter of this CSR for more information.

Site/Sex	Age at Prevalence									
	All Ages <sup>c</sup>	0-9	10-19	20-29	30-39	40-49	50-59	60-69	70+	
Breast	40.005	•					0.400	= 004	40.054	
Males	18,835	0	0	11	76	672	2,123	5,001	10,951	
Females	3,327,552	11	47	3,031	38,197	215,565	597,561	910,098	1,563,042	
Cervix										
Females	256,078	0	81	2,075	14,495	40,908	60,284	61,931	76,305	
Corpus & Uterus, NOS										
Females	710,228	11	35	727	6,574	27,036	100,667	205,938	369,240	
Ovary <sup>d</sup>										
Females	222,060	81	1,038	3,954	7,233	18,751	46,165	61,136	83,701	
Prostate										
Males	3,085,209	45	47	79	338	17,434	240,617	859,940	1,966,708	
Urinary Bladder										
Males	521,201	68	117	524	2,521	9,466	44,105	118,578	345,823	
Females	175,239	79	34	246	972	3,819	14,892	36,157	119,040	
Kidney & Renal Pelvis										
Males	292,058	1,399	2,329	3,006	5,751	20,940	52,404	82,949	123,279	
Females	191,167	1,616	2,455	3,238	5,310	13,603	33,033	47,535	84,377	
Hodgkin Lymphoma										
Males	105,489	209	2,301	9,666	16,550	23,334	24,766	18,035	10,629	
Females	98,576	45	2,147	9,466	16,634	22,567	23,051	14,306	10,361	
Non-Hodgkin Lymphoma										
Males	350,647	831	4,019	8,336	14,494	30,378	61,177	88,332	143,081	
Females	311,349	547	1,536	4,919	9,944	21,497	48,615	75,964	148,327	
Myeloma										
Males	65,283	0	18	87	605	3,537	10,446	19,742	30,849	
Females	53,256	0	0	69	480	2,374	8,379	15,856	26,099	
Leukemia										
Males	219,989	6,599	13,513	14,405	12,981	16,403	29,092	46,712	80,285	
Females	167,739	5,984	10,654	12,441	11,619	12,517	20,169	30,950	63,404	
Acute Lymphocytic Leuk										
Males	44,485	5,568	11,217	11,145	7,420	5,011	2,295	1,096	732	
Females	37,352	5,088	9,067	8,947	6,522	3,972	1,798	1,285	672	
	,	-,	-,	- /	-,	-,	= , 3	=,=30		

U.S. 2014 cancer prevalence counts are based on 2014 cancer prevalence proportions from the SEER 9 registries (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, and Atlanta) and 1/1/2014 U.S. population estimates based on the average of 2013 and 2014 population estimates from the U.S. Bureau of the Census. Prevalence was calculated using the first invasive tumor for each cancer site diagnosed during the previous 39 years (1975-2013).

Cases diagnosed more than 39 years ago were estimated using the completeness index method (Capocaccia et. al. 1997, Merrill et. al. 2000).

Due to rounding, the sum of the age specific estimates may not equal the all ages estimate.